Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients

Bibliography

• World Health Organization; Multiple Sclerosis International Federation. Atlas: multiple sclerosis resources in the world. 2013. Available from: http://www.atlasofms.org/query.aspx [Last accessed 3 February 2014]
   Google Scholar
• Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003;26(11):815-27
   PubMed Web of Science ®Google Scholar
• Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology 2004;62(4):628-31
   PubMed Web of Science ®Google Scholar
• Chan S, Kingwell E, Oger J, et al. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. Mult Scler 2011;17(3):361-7
   PubMed Web of Science ®Google Scholar
• Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001;56(10):1416
   PubMed Web of Science ®Google Scholar
• Pietrosi G, Mandala L, Vizzini GB, et al. Fulminant hepatic failure and autoimmune disorders in patient with multiple sclerosis on interferon beta 1a: a fatal combination? Transpl Int 2008;21(5):502-4
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hayashi P, Bonkovsky HL, et al. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci 2013;58(6):1766-75
   PubMed Web of Science ®Google Scholar
• Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther 2010;31(9):1028-35
   PubMed Web of Science ®Google Scholar
• Brunetti L, Wagner ML, Maroney M, Ryan M. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data. Ann Pharmacother 2013;47(9):1153-60
   PubMed Web of Science ®Google Scholar
• Biogen Idec. Tecfidera (dimethyl fumarate) drug monograph. 2013. Available from: www.tecfidera.com/pdfs/full-prescribing-information.pdf [Last accessed 17 December 2013]
   Google Scholar
• Novartis Pharmaceuticals. Gilenya (Fingolimod capsules) drug monograph. 2012. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf [Last accessed 20 May 2012]
   Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380(9856):1819-28
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137(12):947-54
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354(7):731-9
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-19
   PubMed Web of Science ®Google Scholar
• Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 2009;15(23):2817-33
   PubMed Web of Science ®Google Scholar
• Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89(6):806-15
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010;74(24):2004-15
   PubMed Web of Science ®Google Scholar
• Kingwell E, Bajdik C, Phillips N, et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 2012;135(Pt 10):2973-9
   PubMedGoogle Scholar
• Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler 2004;10(3):298-301
   PubMed Web of Science ®Google Scholar
• Health Canada. Hepatic injury associated with beta-interferon treatment for multiple sclerosis. 2003. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2003/beta_interferon_hpc-cps-eng.php [Last accessed 1 January 2012]
   Google Scholar
• Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49(6):2001-9
   PubMed Web of Science ®Google Scholar
• SWEDEGENE. SWEDEGENE: Genetic causes of adverse drug reactions 2010. Available from: http://www.swedegene.se/methodology.html [Last accessed 1 April 2014]
   Google Scholar
• Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46(11):1323-30
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45
   PubMed Web of Science ®Google Scholar
• Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144(7):1419-25; 25 e1-3; quiz e19-20
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41(7):816-19
   PubMed Web of Science ®Google Scholar
• Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011;141(1):338-47
   PubMed Web of Science ®Google Scholar
• Gurwitz D, Pirmohamed M. Pharmacogenomics: the importance of accurate phenotypes. Pharmacogenomics 2010;11(4):469-70
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v 4.03. 2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf [Last accessed 12 October 2012]
   Google Scholar
• Tremlett H, Seemuller S, Zhao Y, et al. Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients. Neurology 2006;67(7):1291-3
   PubMed Web of Science ®Google Scholar
• Dufour DR. Laboratory guidelines for screening, diagnosis and monitoring of hepatic injury. National Academy of Clinical Biochemistry; Washington, DC, USA: 2000
   Google Scholar
• Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009;50(3):511-17
   PubMed Web of Science ®Google Scholar
• Kowalec K, Yoshida E, Traboulsee A, et al. Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Mult Scler Relat Disord 2013;2:57-9
   PubMed Web of Science ®Google Scholar
• Coppola G, Lanzillo R, Florio C, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol 2006;13(9):1014-21
   PubMed Web of Science ®Google Scholar
• Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247-56
   PubMed Web of Science ®Google Scholar
• Dong MH, Bettencourt R, Brenner DA, et al. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol 2012;10(3):285-90; e1
   PubMed Web of Science ®Google Scholar
• Marriott JJ, Mamdani M, Saposnik G, et al. Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario. Can J Neurol Sci 2013;40(1):67-72
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004;58(1):71-80
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36(2):451-5
   PubMed Web of Science ®Google Scholar
• Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011;8(4):202-11
   PubMed Web of Science ®Google Scholar
• Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30(4):277-94
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42(2):481-9
   PubMed Web of Science ®Google Scholar
• Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther 2012;92(3):332-9
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37(6):410-15
   PubMed Web of Science ®Google Scholar
• Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33(1):155-64
   PubMed Web of Science ®Google Scholar
• Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51(6):2117-26
   PubMed Web of Science ®Google Scholar